Lifeboat Foundation

A team of researchers from Tri Alpha Energy Inc. and Google has developed an algorithm that can be used to speed up experiments conducted with plasma. In their paper published in the journal Scientific Reports, the group describes how they plan to use the algorithm in nuclear fusion research.

As research into harnessing nuclear fusion has progressed, scientists have found that some of its characteristics are too complex to be solved in a reasonable amount of time using current technology. So they have increasingly turned to computers to help. More specifically, they want to adjust certain parameters in a device created to achieve fusion in a reasonable way. Such a device, most in the field agree, must involve the creation of a certain type of plasma that is not too hot or too cold, is stable, and has a certain desired density.

Finding the right parameters that meet these conditions has involved an incredible amount of trial and error. In this new effort, the researchers sought to reduce the workload by using a computer to reduce some of the needed trials. To that end, they have created what they call the “optometrist’s algorithm.” In its most basic sense, it works like an optometrist attempting to measure the visual ability of a patient by showing them images and asking if they are better or worse than other images. The idea is to use the crunching power of a computer with the intelligence of a human being—the computer generates the options and the human tells it whether a given option is better or worse.

Every day, hundreds of thousands of new COVID-19 cases and thousands of new deaths are still being reported worldwide, creating a need for drugs that can combat the disease caused by SARS-CoV-2.

Now, new research led by investigators at Harvard Medical School and Boston Children’s Hospital points to a well-known and widely available drug called disulfiram (marketed as Antabuse) as a possible treatment for COVID-19.

In the retrospective study, published Oct. 28 in PLOS ONE, patients taking disulfiram for alcoholism were less likely to become infected with SARS-CoV-2, and those who did get infected were less likely to die from COVID-19 than those not taking the drug.

Continue reading “Alcoholism treatment drug shows potential with COVID-19” »

This month, the UW team upped their game.

Tapping into both AlphaFold and RoseTTAFold, they tweaked the programs to predict which proteins are likely to tag-team and sketched up the resulting complexes into a 3D models.

Using AI, the team predicted hundreds of complexes—many of which are entirely new—that regulate DNA repair, govern the cell’s digestive system, and perform other critical biological functions. These under-the-hood insights could impact the next generation of DNA editors and spur new treatments for neurodegenerative disorders or anti-aging therapies.

*Food Out Of Thin Air. Just Might Work: Revolutionary protein production from renewable electricity and air.*

Solar Foods was chosen as one of the international winners of @NASA ‘s and @csa_asc ‘s @DeepSpaceFood Challenge Nov 15, 2021!

Continue reading “The secret lab making the most sustainable food in the world | Just Might Work by Freethink” »

A robot-assisted surgery was completed in Israel using the Da Vinci surgical system, by which the surgeon sits at a console and controls the robot.

An artificial intelligence-based method for identifying patients who are at risk for atrial fibrillation has been developed by a team led by researchers at Harvard-affiliated Massachusetts General Hospital and the Broad Institute of MIT and Harvard.

Atrial fibrillation — an irregular and often rapid heart rate — is a common condition that often leads to the formation of clots in the heart that can travel to the brain to cause a stroke. The study was published in Circulation.

The investigators developed the artificial intelligence-based method to predict the risk of atrial fibrillation within the next five years based on results from electrocardiograms (noninvasive tests that record the electrical signals of the heart) in 45,770 patients receiving primary care at MGH.

It is designed to activate white blood cells found in the lymph nodes on the sides and back of the neck to migrate to the brain and trigger clearance of beta-amyloid plaques — one of the hallmarks of Alzheimer’s. I-Mab Biopharma (I-Mab) and Jiangsu Nhwa Pharmaceutical (NHWA) are responsible for the development, manufacturing and commercialization of Protollin.

The trial represents the culmination of nearly 20 years of research led by Dr. Howard L. Weiner, co-director of the Ann Romney Center for Neurologic Diseases at the Brigham.

“The launch of the first human trial of a nasal vaccine for Alzheimer’s is a remarkable milestone,” said Weiner. “Over the last two decades, we’ve amassed preclinical evidence suggesting the potential of this nasal vaccine for AD. If clinical trials in humans show that the vaccine is safe and effective, this could represent a nontoxic treatment for people with Alzheimer’s, and it could also be given early to help prevent Alzheimer’s in people at risk.”

A woman in Argentina has become only the second documented person whose own immune system may have cured her of HIV.

The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38−1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26-fold (95% CI, 1.80−3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.

The duration of effectiveness of SARS-CoV-2 vaccination is not yet known. Here, the authors present preliminary evidence of BNT162b2 vaccine waning across all age groups above 16, with a higher incidence of infection in people who received their second dose early in 2021 compared to later in the year.